These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 23060591)

  • 1. Association between expression of thymidylate synthase, dihydrofolate reductase, and glycinamide ribonucleotide formyltransferase and efficacy of pemetrexed in advanced non-small cell lung cancer.
    Shimizu T; Nakanishi Y; Nakagawa Y; Tsujino I; Takahashi N; Nemoto N; Hashimoto S
    Anticancer Res; 2012 Oct; 32(10):4589-96. PubMed ID: 23060591
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Thymidylate synthase and dihydrofolate reductase expression in non-small cell lung carcinoma: the association with treatment efficacy of pemetrexed.
    Chen CY; Chang YL; Shih JY; Lin JW; Chen KY; Yang CH; Yu CJ; Yang PC
    Lung Cancer; 2011 Oct; 74(1):132-8. PubMed ID: 21367480
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TS, DHFR and GARFT expression in non-squamous cell carcinoma of NSCLC and malignant pleural mesothelioma patients treated with pemetrexed.
    Uramoto H; Onitsuka T; Shimokawa H; Hanagiri T
    Anticancer Res; 2010 Oct; 30(10):4309-15. PubMed ID: 21036757
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reduced folate carrier and folylpolyglutamate synthetase, but not thymidylate synthase predict survival in pemetrexed-treated patients suffering from malignant pleural mesothelioma.
    Mairinger F; Vollbrecht C; Halbwedl I; Hatz M; Stacher E; Gülly C; Quehenberger F; Stephan-Falkenau S; Kollmeier J; Roth A; Mairinger T; Popper H
    J Thorac Oncol; 2013 May; 8(5):644-53. PubMed ID: 23449276
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase II trial of pemetrexed in advanced breast cancer: clinical response and association with molecular target expression.
    Gomez HL; Santillana SL; Vallejos CS; Velarde R; Sanchez J; Wang X; Bauer NL; Hockett RD; Chen VJ; Niyikiza C; Hanauske AR
    Clin Cancer Res; 2006 Feb; 12(3 Pt 1):832-8. PubMed ID: 16467096
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Establishment of pemetrexed-resistant non-small cell lung cancer cell lines.
    Zhang D; Ochi N; Takigawa N; Tanimoto Y; Chen Y; Ichihara E; Hotta K; Tabata M; Tanimoto M; Kiura K
    Cancer Lett; 2011 Oct; 309(2):228-35. PubMed ID: 21742432
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacogenomic assessment of outcomes of pemetrexed-treated patients with adenocarcinoma of the lung.
    Jung M; Lee CH; Park HS; Lee JH; Kang YA; Kim SK; Chang J; Kim DJ; Rha SY; Kim JH; Cho BC
    Yonsei Med J; 2013 Jul; 54(4):854-64. PubMed ID: 23709418
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thymidylate synthase gene copy number as a predictive marker for response to pemetrexed treatment of lung adenocarcinoma.
    Kasai D; Ozasa H; Oguri T; Miyazaki M; Uemura T; Takakuwa O; Kunii E; Ohkubo H; Maeno K; Niimi A
    Anticancer Res; 2013 May; 33(5):1935-40. PubMed ID: 23645741
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thymidylate synthase expression as a predictive biomarker of pemetrexed sensitivity in advanced non-small cell lung cancer.
    Chamizo C; Zazo S; Dómine M; Cristóbal I; García-Foncillas J; Rojo F; Madoz-Gúrpide J
    BMC Pulm Med; 2015 Oct; 15():132. PubMed ID: 26502926
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New data integrating multitargeted antifolates into treatment of first-line and relapsed non-small-cell lung cancer.
    Scagliotti GV; Selvaggi G
    Clin Lung Cancer; 2008; 9 Suppl 3():S122-8. PubMed ID: 19419926
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of pemetrexed in advanced non small-cell lung cancer: special focus on pharmacology and mechanism of action.
    Joerger M; Omlin A; Cerny T; Früh M
    Curr Drug Targets; 2010 Jan; 11(1):37-47. PubMed ID: 19839929
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular Factors Associated with Pemetrexed Sensitivity According to Histological Type in Non-small Cell Lung Cancer.
    Yoshida T; Okamoto T; Yano T; Takada K; Kohno M; Suda K; Takenoyama M; Oda Y; Maehara Y
    Anticancer Res; 2016 Dec; 36(12):6319-6326. PubMed ID: 27919952
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Thymidylate synthase gene amplification predicts pemetrexed resistance in patients with advanced non-small cell lung cancer.
    Shimizu T; Nakagawa Y; Takahashi N; Hashimoto S
    Clin Transl Oncol; 2016 Jan; 18(1):107-12. PubMed ID: 26220094
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro chemosensitivity of freshly explanted tumor cells to pemetrexed is correlated with target gene expression.
    Hanauske AR; Eismann U; Oberschmidt O; Pospisil H; Hoffmann S; Hanauske-Abel H; Ma D; Chen V; Paoletti P; Niyikiza C
    Invest New Drugs; 2007 Oct; 25(5):417-23. PubMed ID: 17534577
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pemetrexed for previously treated patients with non-small cell lung cancer and differences in efficacy according to thymidylate synthase expression.
    Igawa S; Ryuge S; Wada M; Otani S; Maki S; Takakura A; Katono K; Sasaki J; Sato Y; Masuda N
    Chemotherapy; 2012; 58(4):313-20. PubMed ID: 23147191
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association between TYMS expression and efficacy of pemetrexed-based chemotherapy in advanced non-small cell lung cancer: a meta-analysis.
    Wang T; Chuan Pan C; Rui Yu J; Long Y; Hong Cai X; De Yin X; Qiong Hao L; Li Luo L
    PLoS One; 2013; 8(9):e74284. PubMed ID: 24040222
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Significance of folate receptor alpha and thymidylate synthase protein expression in patients with non-small-cell lung cancer treated with pemetrexed.
    Christoph DC; Asuncion BR; Hassan B; Tran C; Maltzman JD; O'Shannessy DJ; Wynes MW; Gauler TC; Wohlschlaeger J; Hoiczyk M; Schuler M; Eberhardt WE; Hirsch FR
    J Thorac Oncol; 2013 Jan; 8(1):19-30. PubMed ID: 23242435
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The pemetrexed-containing treatments in the non-small cell lung cancer is -/low thymidylate synthase expression better than +/high thymidylate synthase expression: a meta-analysis.
    Wang L; Wang R; Pan Y; Sun Y; Zhang J; Chen H
    BMC Cancer; 2014 Mar; 14():205. PubMed ID: 24641970
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Thymidylate synthase expression and outcome of patients receiving pemetrexed for advanced nonsquamous non-small-cell lung cancer in a prospective blinded assessment phase II clinical trial.
    Nicolson MC; Fennell DA; Ferry D; O'Byrne K; Shah R; Potter V; Skailes G; Upadhyay S; Taylor P; André V; Nguyen TS; Myrand SP; Visseren-Grul C; Das M; Kerr KM
    J Thorac Oncol; 2013 Jul; 8(7):930-9. PubMed ID: 23722170
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacogenetic study of patients with advanced non-small cell lung cancer (NSCLC) treated with second-line pemetrexed or pemetrexed-carboplatin.
    Tiseo M; Giovannetti E; Tibaldi C; Camerini A; Di Costanzo F; Barbieri F; Burgers JA; Vincent A; Peters GJ; Smit EF; Ardizzoni A
    Lung Cancer; 2012 Oct; 78(1):92-9. PubMed ID: 22889494
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.